Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients

Journal of Surgical Oncology

Volumn 88, Issue 4, 2004, Pages 240-247

  Romano, Fabrizio ^a,c   Cesana, Giovanni ^b   Berselli, Mattia ^a   Piacentini, Maria Gaia ^a   Caprotti, Roberto ^a   Bovo, Giorgio ^a   Uggeri, Franco ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

Gastric cancer; IL 2; Immunodeficiency; Lymphocytopenia; Postoperative; Tumor infiltrating lymphocytes (TILs)

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CELL INFILTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG TOLERABILITY; EOSINOPHIL; EVALUATION; FEMALE; FIBROSIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOTHERAPY; LOW DRUG DOSE; LYMPHADENECTOMY; LYMPHOCYTE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEUTROPHIL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STOMACH ADENOCARCINOMA; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CD4-CD8 RATIO; DISEASE-FREE SURVIVAL; FEMALE; GASTRECTOMY; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOPENIA; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; STOMACH NEOPLASMS;

EID: 10044275272     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20155     Document Type: Article

References (48)

1. Lissoni P, Barni S, Rovelli F: Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Oncology 1991;48:125-127.
2. Monson JRT, Ramsden C, Guillou PJ: Decreased IL-2 production in patients with gastrointestinal cancer. Br J Surg 1986;73:483-486.
3. Kambayashi T, Alexander HR, Fong M, et al.: Potential involvement of IL-10 in suppressing tumor-associated macrophages. J Immunol 1995;154:3383-3390.
4. Fisher JR, Schindel M, Stein N, et al.: Selective suppression of cytokine secretion in patients with small-cell lung cancer. Ann Oncol 1995;6:921-926.
5. De Vita F, Turitto G, Di Grazia M, et al.: Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small cell lung cancer. Tumori 1998;84:33-38.
6. Un-Sup K, Papatestas AE, Aufses AH: Prognostic significance of peripheral lymphocyte counts and carcinoembryonic antigens in colorectal cancer. J Sug Oncol 1976;8:257-262.
7. Yamaguchi K, Maeda S, Kitamura K: Prognostic factors in colorectal carcinoma: Significance of peripheral T lymphocytes. Int Surg 1989;74:232-239.
8. Lundy J, Ford CM: Surgery, trauma amd immune suppression. Ann Surg 1983;191:434-438.
9. Costantin MB, Menzonian JO, Nimberg RB, et al.: Association of a circulating immunosoppressive polypeptide with operative and accidental trauma. Ann Surg 1977;185:73-88.
10. Brivio F, Lissoni P, Alderi G, et al.: Preoperative interleukin-2 subcutaneous therapy may prolong survival time in advanced colorectal cancer patients. Oncology 1996;53:263-268.
11. Allen A, Hogg N: Monocytes and other infiltrating cells in human colorectal tumors identified by monoclonal antibodies. Immunology 1985;55:289-299.
12. Balch CM, Riley LB, Base YJ, et al.: Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 1990;125:200-205.
13. Wintzer HO, Bohle W, Von Kleist S: Study of the relationship between immunohistochemically demonstrated lymphocytes infiltrating breast carcinomas and patient's survival. J Cancer Res Clin Oncol 1991;117:163-167.
14. Mihm M, Clemente C, Cascinelli N: Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996;74:43-47.
15. Naukkarinen A, Syrjanen K: Quantitative immunohistochemical analysis of mononuclear infiltrates in breast carcinoma, correlation with tumor differentiation. J Pathol 1990;160:217-222.
16. Naito Y, Saito K, Shiiba K, et al.: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-3494.
17. Menard S, Tomasic G, Casalini P, et al.: Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997;3:817-819.
18. Clemente C, Collini P: TIL as a prognostic histopathologic parameter in cutaneous melanoma. Melanoma Res 1993;3:26-29.
19. Lucin K, Iternicka Z, Jonjic N: Prognostic significance of T-cell infiltrates, expression of beta-2-microglobulin and HLA-DR antigens in breast carcinoma. Pathol Res Pract 1994;190:1134-1140.
20. Setala LP, Kosma VM, Marin S, et al.: Prognostic factors in gastric cancer: The value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration. Br J Cancer 1996;74:766-772.
21. Brivio F, Lissoni P, Tisi E, et al.: Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients. Oncology 1992;49:215-218.
22. Brivio F, Lissoni P, Barni S, et al.: Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: A phase II study. Eur J Surg 1993;159:43-47.
23. Oncology Report.
24. Margolin KA: Interleukin-2 and the treatment of renal cancer. Semin Oncol 2000;27:194-203.
25. Rosemberg M: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
26. Cerea K, Romano F, Ferrari Bravo A, et al.: Phase IB study on prevention of surgery-induced immunodeficiency with preoperative administration of low-dose subcutaneous IL-2 in gastric cancer patients. J Surg Oncol 2001;78:32-37.
27. Ropponnen KM, Eskilinen MI, Lipponen PK, et al.: Prognostic value of tumor-infiltrating lyphocytes (TIL) in colorectal cancer. J Pathol 1997;182:318-324.
28. Castelino DJ, McNair P, Kay TW: Lymphocytopenia in a hospital population - What does it signify? Aust NZ J Med 1997;27:170-174.
29. Lazarou SA, Barbul A, Wasserkrug HL, et al.: The wound is a possible source of posttraumatic immunosuppression. Arch Surg 1989;124:1429-1431.
30. Hernberg M: Lymphocyte substes as prognostic markers for cancer patients receiving immunomodulative therapy. Med Oncol 1999;16:145-153.
31. Nakata B, Chung KH, Kato Y, et al.: Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer. Br J Cancer 1998;77:1820-1824.
32. Saito H, Tsujitani S, Ikeguchi M, et al.: Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer. Oncology 1999;56:253-258.
33. Brivio F, Fumagalli L, Lissoni P, et al.: Impact of pre-surgical immunotherapy with interleukin-2 on immunobiological surgery-induced deficiencies in patients with colorectal cancer. Int J Surg Sciences 1995;2:255-258.
34. Masotti A, Morandini G, Ortolani R, et al.: Phase II randomized study of pre-operative IL-2 administration in operable NSCLC. Lung Cancer 1998;20:191-202.
35. Fyfe G, Fisher RI, Rosemberg SA, et al.: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant IL-2 therapy. J Clin Oncol 1995;13:688-696.
36. Atzpodien J, Korfer A, Franks C, et al.: Home therapy with recombinant interleukin-2 and interferon alpha 2b in advanced human malignancies. Lancet 1990;335:1509-1512.
37. Lissoni P, Barni S, Ardizzoia A, et al.: Prognostic factors of the clinical response to sucutaneous immunotherapy with IL-2 in patients with metastatic RCC. Oncology 1994;51:59-62.
38. Brivio F, Lissoni P, Brivio O, et al.: Timing and schedule of perioperative immunotherapy with interleukin-2 in oncological surgery. J Em Surg Int Care 1996;19:59-62.
39. Villegas FR, Coca S, Villarrubia VG, et al.: Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002;35: 23-28.
40. Friedl J, Stift A, Paolini P, et al.: Tumor antigen pulsed dendritic cells enhance the cytolityc activity of tumor-infiltrating lymphocytes in human hepatocellular cancer. Cancer Biother Radiopharm 2000;15:477-486.
41. Coca S, Perez-Piqueras J, Martinez D, et al.: The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997;79:2320-2328.
42. Vesalainen S, Lipponen P, Taljia M, et al.: Histological grade, perineural infiltration, tumor-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994;30:1797-1803.
43. Hakansson L, Adell G, Boeryd B, et al.: Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: An immunohistological analysis. Br J Cancer 1997;75:374-380.
44. Diederichsen AC, Zeuthen J, Christensen PB, et al.: Characterisation of tumor infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer. Eur J cancer 1999;35:721-726.
45. Lee WJ, Chang KJ, Lee CS, et al.: Selective depression of T-lymphocyte subsets in gastric cancer patients: An implication of immunotherapy. J Surg Oncol 1994;55:165-169.
46. Santin AD, Hermonat PL, Ravaggi A, et al.: Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest 2001;51:254-261.
47. Schumacher K, Haensch W, Roefzaad W, et al.: Prognostic significance of activated CD8 T cell infiltration within esophageal carcinomas. Cancer Res 2001;61:3932-3936.
48. Cuschieri A, Feyers P, Fielding J, et al.: Postoperative morbidity and mortality after D1 and D2 resection for gastric cancer. Preliminary results of the MRC randomized controlled surgical trial. Lancet 1996;437:176-182.